<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>3(5)</volume><submitter>Klein J</submitter><pubmed_abstract>Synthetic biology has been heralded as a new bioengineering platform for the production of bulk and specialty chemicals, drugs, and fuels. Here, we report for the first time a series of 74 novel compounds produced using a combinatorial genetics approach in baker's yeast. Based on the concept of "coevolution" with target proteins in an intracellular primary survival assay, the identified, mostly scaffold-sized (200-350 MW) compounds, which displayed excellent biological activity, can be considered as prevalidated hits. Of the molecules found, >75% have not been described previously; 20% of the compounds exhibit novel scaffolds. Their structural and physicochemical properties comply with established rules of drug- and fragment-likeness and exhibit increased structural complexities compared t</pubmed_abstract><journal>ACS synthetic biology</journal><pagination>314-23</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4046787</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Yeast synthetic biology platform generates novel chemical structures as scaffolds for drug discovery.</pubmed_title><pmcid>PMC4046787</pmcid><pubmed_authors>Boussemghoune T</pubmed_authors><pubmed_authors>Heal JR</pubmed_authors><pubmed_authors>Tange TO</pubmed_authors><pubmed_authors>Heim J</pubmed_authors><pubmed_authors>Hamilton WD</pubmed_authors><pubmed_authors>Hatsch A</pubmed_authors><pubmed_authors>Klein J</pubmed_authors><pubmed_authors>Jaeschke G</pubmed_authors><pubmed_authors>Delegrange F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Yeast synthetic biology platform generates novel chemical structures as scaffolds for drug discovery.</name><description>Synthetic biology has been heralded as a new bioengineering platform for the production of bulk and specialty chemicals, drugs, and fuels. Here, we report for the first time a series of 74 novel compounds produced using a combinatorial genetics approach in baker's yeast. Based on the concept of "coevolution" with target proteins in an intracellular primary survival assay, the identified, mostly scaffold-sized (200-350 MW) compounds, which displayed excellent biological activity, can be considered as prevalidated hits. Of the molecules found, >75% have not been described previously; 20% of the compounds exhibit novel scaffolds. Their structural and physicochemical properties comply with established rules of drug- and fragment-likeness and exhibit increased structural complexities compared t</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 May</publication><modification>2026-05-03T11:07:51.3Z</modification><creation>2019-03-27T01:29:31Z</creation></dates><accession>S-EPMC4046787</accession><cross_references><pubmed>24742115</pubmed><doi>10.1021/sb400177x</doi></cross_references></HashMap>